Università di Udine-ko ikertzaileekin lankidetzan egindako argitalpenak (26)

2023

  1. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  2. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

    Critical Care, Vol. 27, Núm. 1

2022

  1. Identification of COVID-19 patients at risk of hospital admission and mortality: a European multicentre retrospective analysis of mid-regional pro-adrenomedullin

    Respiratory Research, Vol. 23, Núm. 1

2020

  1. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?

    Clinical Microbiology and Infection, Vol. 26, Núm. 8, pp. 1024-1033

  2. Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness

    Cancer Research, Vol. 80, Núm. 3, pp. 624-638

  3. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

  4. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 4

  5. Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study

    Infectious Diseases and Therapy, Vol. 9, Núm. 1, pp. 151-163

  6. Factors associated with the development of septic shock in patients with candidemia: A post hoc analysis from two prospective cohorts

    Critical Care, Vol. 24, Núm. 1

2019

  1. Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis

    Mycoses, Vol. 62, Núm. 5, pp. 441-449

  2. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with Pseudomonas aeruginosa bacteraemia (IRONIC study): Study protocol of a retrospective multicentre international study

    BMJ Open, Vol. 9, Núm. 5

  3. Influence of age on the clinical efficacy of tigecycline in severely ill patients

    Journal of Global Antimicrobial Resistance, Vol. 18, pp. 199-206

  4. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    Annals of Oncology, Vol. 30, Núm. 5, pp. 766-773

  5. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: A prospective pilot study - Authors' response

    Journal of Antimicrobial Chemotherapy

  6. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

    Critical Reviews in Oncology/Hematology, Vol. 134, pp. 39-45

2018

  1. Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 37, Núm. 10, pp. 1993-2000

  2. T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: A prospective pilot study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv6-iv12

  3. T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study

    Journal of Antimicrobial Chemotherapy, Vol. 73, pp. iv13-iv19

  4. Tailoring adjuvant endocrine therapy for premenopausal breast cancer

    New England Journal of Medicine, Vol. 379, Núm. 2, pp. 122-137

2017

  1. Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study

    Intensive Care Medicine, Vol. 43, Núm. 4, pp. 509-518